Postoperative nausea and vomiting (PONV) is among the most common after surgery adverse events, which occur during the first 24 hours to 48 hours post surgery in patients. It has been observed that, on an average 20% to 30% of patients undergoing surgery suffer from vomiting and nausea postoperatively. The incidence of PONV depends on variety of factors, including type of surgery, gender and anesthetic drugs used. Generally, the consequences of PONV are minor, but the impact on medical resources and patient comfort can be significant. At present, the postoperative nausea and vomiting treatment market is expected to grow at a significant rate due to the high incidence rate of postoperative complications, which makes this industry a promising market venture.
Download Exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2969
From the geographical perspective, North America and Europe are the largest markets for postoperative nausea and vomiting treatment market due to the elevated number of surgical procedures performed and high incidence rate of post surgery complications such as retching and dizziness. It is also observed that, after anesthesia cessation, PONV is the common cause of patient dissatisfaction. According to the International Anesthesia Research Society, more than 40 million undergo various surgeries annually in the U.S. and more than 100 million patients globally with almost 30% of the patients experiencing PONV.
Studies also suggest that patients across North America and Europe often pay more than USD 100 to avoid postoperative complications. Thus, this huge base of patients suffering from postoperative nausea and vomiting is likely to boost the growth of the overall PONV treatment market. However, other regions such as South East Asia and Africa are some of the potential regions that are likely to grow in the near future.
The primary factors contributing to the growth of this market are rise in incidence rate of postoperative complications such as nausea, dizziness and vomiting along with increased numbers of surgical procedures performed among population. Moreover, introduction of promising drugs in this market is likely to boost the overall postoperative nausea and vomiting treatment market due to the high success and effectiveness rate of the potential molecules. Furthermore, increasing government support for developing novel therapies and personalized medicines along with high research and development initiatives on the development of cost-effective drugs are expected to fuel the growth of this market.
Additionally, advanced drug delivery technologies such as microneedle arrays and biodegradable particles along with increased focus on retaining superior quality of life are some of the factors that might contribute to the growth of this market. However, rise in overall healthcare expenditure, tedious regulatory approval and product availability are some of the market-restraining factors that might hinder the growth of the post operative nausea and vomiting treatment market in the near future.
Currently, the postoperative nausea and vomiting treatment market is a burgeoning and promising market venture due to the high incidence of post surgery complications such as vomiting and dizziness along increased number of surgical procedures. However, at present the market is highly fragmented owing to the involvement of many established as well as emerging players in this industry. Some of the key market players operating in this market are Acacia Pharma Ltd., Actavis plc, AstraZeneca plc and GlaxoSmithKline plc, amongst others.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.